deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02302807

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

Sponsor: Hoffmann-La Roche

Conditions Bladder Cancer
Interventions Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody Docetaxel Paclitaxel Vinflunine
Updated 16 times since 2017 Last updated: Jul 5, 2019 Started: Jan 13, 2015 Primary completion: Mar 13, 2017 Completion: Nov 8, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bladder Cancer, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 16 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Sep 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Feb 2019 — Sep 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  6. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Dec 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  9. May 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Adelaide, Australia , Aichi, Japan , Amsterdam, Netherlands , Angers, France , Antwerp, Belgium , Aomori, Japan , Arezzo, Italy , Athens, Greece , Atlanta, United States and 176 more locations